SCIENCE Publications

Targeted transcriptional downregulation of MYC using epigenomic controllers demonstrates antitumor activity in hepatocellular carcinoma models
William Senapedis, Kayleigh M. Gallagher, Elmer Figueroa, Jeremiah D. Farelli, Robert Lyng, J. Graeme Hodgson, Charles W. O’Donnell, Joseph V. Newman, Madison Pacaro, Stephen K. Siecinski, Justin Chen, and Thomas G. McCauley
Tuned Upregulation of Diverse Gene Targets using Programmable Epigenomic Controllers
Poster Presentation at ASGCT 2024
Detection and quantification of site-specific DNA methylation from liquid biopsies as a pharmacodynamic biomarker of OTX-2002, a novel MYC-targeting epigenomic controller
Poster Presentation at AACR 2024
Targeted epigenomic control of MYC as a strategy to treat EGFR inhibitor-resistant NSCLC
Poster Presentation at AACR 2024
Induction of Hepatocyte Nuclear Factor 4 alpha (HNF4α) P1-isoforms Using a Selective Epigenomic Controller
Poster Presentation at AASLD 2023
Targeting CXCL9/CXCL10/CXCL11 Using Novel Epigenomic Controllers for the Treatment of Inflammatory Liver Disease
Poster Presentation at AASLD 2023
Design and Characterization of a Programmable Epigenomic Controller Demonstrating Multiplexed Targeting of the CXCL1-8 Gene Cluster for Treatment of Inflammatory Disorders
Poster Presentation at International mRNA Health Conference
Targeted epigenomic modulation of MYC enhances responses to immune checkpoint and EGFR inhibitors in preclinical models of NSCLC
Poster Presentation at AACR-NCI-EORTC 2023.
Effect of MYC-Targeting Programmable Epigenomic mRNA Therapeutics on TME and Immunotherapy Responses.
Poster Presentation at ASCO 2023.
Targeted Epigenomic Control of the MYC Oncogene Robustly Inhibits Survival and Growth of Non-Small Cell Lung Cancer Organoid and Xenograft Models.
Poster Presentation at 2023 Gordon Research Conference on Cancer Genetics and Epigenetics.
A phase 1/2 open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of OTX-2002 as a single agent and in combination with standard of care in patients with hepatocellular carcinoma and other solid tumor types known for association with the MYC oncogene (MYCHELANGELO I)
Poster Presentation at ASCO GI 2023
Drugging the epigenome in the age of precision medicine
Feehley T, O'Donnell CW, Mendlein J, Karande M, McCauley T. Clin Epigenetics. 2023 Jan 11;15(1):6.

Reach out regarding partnership opportunities, careers, our mission, or other inquiries.

Contact Us
Scroll to Top